Upcoming event

Tags

Show all

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

European Urology, August 2019

Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study

European Urology, September 2019

Prospective validation of gallium-68 PSMA-PET/CT in primary staging of prostate cancer patients

The Journal of Urology, September 2019

A 25-year period analysis of other-cause mortality in localized prostate cancer

Clinical Genitourinary Cancer, July 2019

Performance of combined magnetic resonance imaging/ultrasound fusion-guided and systematic biopsy of the prostate in biopsy-naïve patients and patients with prior biopsies

European Urology Focus, July 2019

MRI-targeted or standard biopsy for prostate-cancer diagnosis

The new england journal of medicine 2018 May 10, Volume 378, Issue 19, Pages 1767-1777

Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer

European Urology, July 2019

Robust health utility assessment among long-term survivors of prostate cancer: Results from the cancer of the prostate strategic urologic research endeavor registry

European Urology, July 2019

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

The Lancet Journal, June 2019

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens

BJU Int., July 2019

Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer

European Urology, June 2019

Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database

European Urology Oncology, Volume 1, Issue 6, December 2018, Pages 467-475

PreviousNext